No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
EXAS240719P40000
- 0.04
- +0.01+33.33%
15min DelayClose Jul 17 11:18 ET
0.04High0.04Low
0.04Open0.03Pre Close1 Volume485 Open Interest40.00Strike Price4.00Turnover135.92%IV19.06%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type-0.0202Delta0.0094Gamma1234.25Leverage Ratio-0.0364Theta-0.0001Rho-24.88Eff Leverage0.0019Vega
Intraday
- 5D
- Daily
News
Peeling Back The Layers: Exploring Exact Sciences Through Analyst Insights
Analysts' ratings for Exact Sciences (NASDAQ:EXAS) over the last quarter vary from bullish to bearish, as provided by 8 analysts.In the table below, you'll find a summary of their recent ratings,
Exact Sciences Is Maintained at Buy by Goldman Sachs
Exact Sciences Is Maintained at Buy by Goldman
Express News | Goldman Sachs Maintains Buy on Exact Sciences, Lowers Price Target to $75
Exact Sciences Awards Grants to 28 Organizations Focused on Increasing Colorectal Cancer Screening
Since its launch in 2022, the FOCUS Program has awarded more than $4.5 million to over 75 organizations throughout the United StatesMADISON, Wis.--(BUSINESS WIRE)--Exact Sciences, a leading provider
Exact Sciences Corporation (EXAS) Slipped Over Investors' Concerns
These Are the Stocks With the Highest Increase in Short Interest Within Life Sciences and Diagnostics - Baird
Comments
$Exact Sciences(EXAS.US$ guys relax sooner or later this will grow just not so soon
1
1
$Exact Sciences(EXAS.US$ whats happening? why it keeps dropping?
$Exact Sciences(EXAS.US$ Good opportunity to buy after correction, "not today" I shall buy in next week once volatility minimized. Good AI stoks but you can see good return not before 2025. I am bullish on it and it will remain my best pick for next 3-5 years invetment tenure.
2
Exact Sciences' progress has failed to meet high market expectations, yet its consistent revenue growth suggests it may be worth further investigation. The company's performance has underperformed the broader market, which gained around 31%.
2
Read more
Baboompiak : yup holding onto 100 shares at 57.5